蔣智宏^1,2、洪健華²、黃昭淵²

¹臺北榮民總醫院員山分院 泌尿外科

²臺灣大學附設醫院 泌尿部

Public Chinese Prostate Cancer Professional Series-2：Updated Treatment for Clinically Localized/Regional Lymph Node Invasion Prostate Cancer (translated from NCCN Prostate Cancer Guidelines 2023 V1)

Chih-Hung Chiang^1,2、Jian‑Hua Hong²、Chao‑Yuan Huang²

¹ Department of Urology, Taipei Veterans General Hospital, Yuan-Shan Branch；

² Departments of Urology, National Taiwan University Hospital

Purpose：There are few specialized Chinese series on prostate cancer (PCa). This article is completely translated into Chinese according to the NCCN PCa Guideline Version 1. 2023. It is hoped that through the clear and easy-to-understand professional Chinese PCa series introduction, patients and their families can get the most correct and complete understanding from accurate biopsy diagnosis to the latest PCa treatment methods.

Materials and Methods：This section is translated from the NCCN PCa Guidelines Versions 1. 2023.

Results：According to expected patient survival and initial risk stratification, there are four basic treatment combinations available for "Clinically Localized PCa"：1. Active Surveillance/Observation、2. External Radiotherapy, Proton Therapy($), Heavy Particle Therapy($)、3. Radical Prostatectomy ± Lymph Node Dissection (Da Vinci/Senhance Robotic Surgical System) and 4. Androgen Deprivation Therapy. According to expected patient survival >/£ 5 years, there are four basic treatment combinations available for "Regional Lymph Node Invasion PCa"：1. External Radiotherapy、2. Androgen Deprivation Therapy、3. Radical Prostatectomy + (extended) Lymph Node Dissection (Da Vinci/Senhance Robotic Surgical System)、4. Observation.

Conclusion：Objective expected patient survival time、initial risk stratification and adequate communication are the key to the treatment selection of "Clinically Localized PCa" and "Regional Lymph Node Invasion PCa".